Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEBRO Study
2024-519749-31-00Phase 4Authorised
- Sponsor
- Institute for Study Research Education and Therapy of Vascular Heart Brain and Kidney
- Start
- Jan 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of eplerenone and irbesartan in hypertension (HTN) (2 arms), sponsored by Institute for Study Research Education and Therapy of Vascular Heart Brain and Kidney. Primary endpoint: Change in 24-hour ambulatory blood pressure at 24 weeks. Planned start Jan 2025; status: authorised.
02
Drugs
eplerenoneirbesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2024-519749-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519749-31-00.